PAS
AMPE

Park Avenue Securities’s Ampio Pharmaceuticals Inc. AMPE Stock Holding History

Park Avenue Securities’s Portfolio AMPE Stock Details AMPE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q3 		– Sell
-245
Closed -$12K – 1182
2022
Q2 		$12K Buy
+245
New +$18.2K ﹤0.01% 1114

Other funds holding AMPE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $950M AUM 20.72% 1-Year Est. Return
PCMC
Private Capital Management (Colorado) Denver, Colorado $501M AUM 17.09% 1-Year Est. Return
SA
Shilanski & Associates Anchorage, Alaska $376M AUM 19.08% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CC
Courier Capital Buffalo, New York $2B AUM 24.36% 1-Year Est. Return

Park Avenue Securities's AMPE Position: Q3 2022 in Review

Park Avenue Securities sold out of Ampio Pharmaceuticals Inc. (AMPE) in Q3 2022, closing a stake of 245 shares — an estimated $12K sold.

Park Avenue Securities first reported a position in AMPE in Q2 2022 and held it in 1 quarter. The position peaked at $12K in Q2 2022. 95 funds tracked by Wall St. Rank hold AMPE as of Q3 2022.

  • Park Avenue Securities reported no remaining Ampio Pharmaceuticals Inc. position as of Q3 2022 after selling out during the quarter.
  • Park Avenue Securities sold 245 Ampio Pharmaceuticals Inc. shares in Q3 2022, an estimated $12K.
  • Park Avenue Securities first reported a position in Ampio Pharmaceuticals Inc. in Q2 2022 and held it in 1 quarter.
  • Park Avenue Securities's Ampio Pharmaceuticals Inc. position peaked at $12K in Q2 2022.
  • 95 funds tracked by Wall St. Rank held Ampio Pharmaceuticals Inc. as of Q3 2022.

Based on Park Avenue Securities's 13F filing for Q3 2022, filed 1 Nov 2022.